Xenon Pharmaceuticals Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed February 29, 2024. The filing is an annual report, not a quarterly report. Amounts are in U.S. dollars unless stated otherwise.
Business context
Xenon is a clinical-stage neuroscience biopharmaceutical company with no products approved for sale and no product-sales revenue. Its lead candidate, XEN1101, is being developed for epilepsy and major depressive disorder (MDD). The company also has partnered programs, including NBI-921352 with Neurocrine Biosciences.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $0 | $9.4 million |
| Research and development expense | $167.5 million | $105.8 million |
| General and administrative expense | $46.5 million | $32.8 million |
| Total operating expenses | $214.1 million | $138.6 million |
| Net loss | $182.4 million | $125.4 million |
| Net cash used in operating activities | $145.3 million | $98.4 million |
| Cash, cash equivalents and marketable securities, at year-end | $930.9 million | $720.8 million |
- Revenue fell to zero as Neurocrine collaboration performance obligations and research services were completed in 2022; no collaboration milestones were recognized in 2023. Xenon has not generated product-sales revenue.
- R&D expense rose $61.7 million, primarily from XEN1101 Phase 3 epilepsy trials, manufacturing activities, the X-NOVA MDD study and higher personnel and stock-based compensation costs. G&A rose $13.7 million, mainly due to personnel, stock compensation and professional fees.
- Other income was $31.4 million, including $27.6 million of interest income and a $3.6 million unrealized gain on trading securities. The net loss widened by $57.0 million year over year.
- Cash used in investing activities was $117.2 million; cash provided by financing activities was $353.5 million, primarily from share and pre-funded warrant issuances. The November 2023 public offering generated approximately $324.0 million net.
- Total liabilities were $36.9 million, including $10.9 million of operating lease liabilities; the balance sheet reports no borrowings. The filing lists $12.5 million of future minimum lease payments. No profitability or operating margins are meaningful given the absence of revenue.
- Management expected year-end cash and marketable securities to fund operating and capital needs for at least 12 months from the filing date, while cautioning that plans or funding needs may change. Accumulated deficit was $665.1 million.
Material developments and outlook
- XEN1101 epilepsy: Two Phase 3 focal-onset seizure trials, X-TOLE2 and X-TOLE3, were underway; management expected X-TOLE2 enrollment to finish in late 2024 to early 2025. The X-ACKT Phase 3 trial is studying primary generalized tonic-clonic seizures. The X-TOLE Phase 2b open-label extension was extended from five to seven years. Reported interim extension data showed sustained seizure reductions and no new safety signals, but these are not confirmatory Phase 3 results.
- XEN1101 MDD: In the 168-patient Phase 2 X-NOVA trial, the primary week-six MADRS endpoint showed a clinically meaningful numerical difference for 20 mg versus placebo, but it was not statistically significant (difference 3.04; p=0.135). Statistical significance was reported on certain secondary measures, including HAM-D17, SHAPS and week-one MADRS. Xenon anticipated an FDA end-of-Phase 2 meeting in April 2024 and expected to begin a three-trial Phase 3 program in the second half of 2024.
- Partnered program: Neurocrine reported that NBI-921352 failed to show meaningful seizure-frequency reduction in a Phase 2 adult focal-onset seizure trial; no further development in that indication was planned at the time. A pediatric SCN8A-DEE Phase 2 study remained underway.
- Capital and spending: The company raised substantial equity capital in 2023 and expects expenses and losses to continue, with R&D spending likely to rise as programs advance. It may seek further equity, debt, collaboration or other financing; future financing could dilute shareholders or constrain operations.
Risks, contingencies and other notable items
- Development and regulatory outcomes remain uncertain; Phase 3 results may differ from earlier studies, trials may be delayed or fail, and approval or commercial success is not assured. Xenon identifies XEN1101 as central to its prospects.
- The company relies on third parties for clinical trials and manufacturing, and reports risks from patient enrollment, supply, regulatory requirements, competition, reimbursement and the ability to establish commercial capabilities.
- As a clinical-stage company with ongoing losses and no product revenue, Xenon may need additional capital. Equity issuance could dilute shareholders; management stated current resources were expected to cover at least the next 12 months, not all future development and commercialization costs.
- Cash and marketable securities totaled $930.9 million, with exposure to interest-rate and Canadian-dollar movements. The company estimated a 100-basis-point unfavorable interest-rate change would reduce marketable-security fair value by about $5.7 million. It did not hedge foreign-currency exposure.
- Potential future regulatory milestone payments to 1st Order Pharmaceuticals total up to $6.0 million; future minimum lease payments total $12.5 million. Management reported no material legal proceedings. Indemnification obligations are described as potentially unlimited, though no liability was recorded and the company maintains insurance.
- KPMG issued unqualified opinions on the financial statements and internal control over financial reporting; it reported no critical audit matters. Management and the auditor concluded internal control was effective as of December 31, 2023.
Key facts investors should verify
- Progress, enrollment timing and eventual primary-endpoint results for X-TOLE2, X-TOLE3 and X-ACKT, together with the full safety profile and any material protocol or timeline changes.
- Whether FDA feedback after the planned MDD meeting supports the Phase 3 design, and whether subsequent trials confirm clinically meaningful efficacy—especially given X-NOVA’s nonsignificant primary endpoint.
- How the NBI-921352 adult-trial setback affects potential collaboration milestones and the remaining pediatric SCN8A-DEE program.
- Quarterly cash burn, investment balances and maturity profile, financing activity, share-count dilution, and whether management’s stated runway remains valid as development costs increase.
- Any changes in product development plans, manufacturing readiness, regulatory expectations, collaboration terms, or potential milestone and royalty economics.